AMGEN (AMGN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does AMGEN (AMGN) do?
AMGEN Inc (AMGN) is a U.S.-listed company in Healthcare (Drug Manufacturers - General). What it does: Manufactures and sells biologic therapies for oncology, heart disease, inflammation, and rare disorders. It discovers, manufactures, and distributes biologics and complex medicines through proprietary cell-culture processes. It is worth $237.36B on the market and sold $38.98B over the last year.
- Market cap
- $237.36B
- P/E ratio
- 25.5×
- Annual sales
- $38.98B
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Brief updated
- Nov 14, 2026
Brands and businesses behind AMGN
- Prolia: A prescription bone density injection that generates sales from patients treating postmenopausal osteoporosis.
- Enbrel: An injectable biologic treatment that generates revenue through prescriptions for rheumatoid arthritis and plaque psoriasis.
- Repatha: A self-injected cholesterol medicine that generates revenue by lowering low-density lipoprotein levels in cardiovascular patients.
- Otezla: An oral pill that produces revenue by treating plaque psoriasis and psoriatic arthritis in adult patients.
- Xgeva: An injectable prescription drug that earns revenue by preventing serious bone fractures in patients with cancer.
- Tepezza: An infused biologic medicine that generates revenue by treating thyroid eye disease symptoms like bulging eyes.
AMGN’s flags, in plain English
Each flag is a number from AMGEN’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.
Wide Gross Margin
Gross margin of 74% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earns Its Keep
Earns 78.4% a year on shareholders' money. The company earns a healthy return on the money its shareholders have put in.
Fat Margins
Profit margin of 24.1%. The company keeps a healthy share of each sale as profit, which gives it room when costs jump.
Debt Is Driving
Heavy debt, 376% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.
2 more green flags open with the free trial. Try it free for 7 days.
Questions about AMGN
How big is AMGEN?
AMGEN’s market cap is $237.36B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $38.98B: what customers paid the company over the last year, before any costs.
What is AMGN’s P/E ratio?
AMGN’s P/E ratio is 25.5×. Investors pay about 25.5 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with AMGN?
Total debt stands at 42 percent of corporate assets following large debt-financed acquisitions. That is one risk on AMGEN’s card. Its first risk flag is Debt Is Driving, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From AMGEN’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. AMGN’s filings on SEC.gov. The Margin Monkey is research, not advice.
